Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...

On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years ...

Excluding these special items, adjusted loss per share was 72 cents compared with a loss of 85 cents per share in the ...

Denali has two wholly-owned, late-stage development programs — DNL310 for (Hunter syndrome) and DNL343 (eIF2B activator) — for amyotrophic lateral sclerosis (ALS). DNL310, or tividenofusp alfa, is an ...

Neurosense Therapeutics (NASDAQ:NRSN) is developing novel treatments for neurodegenerative diseases like amyotrophic lateral ...

The University of Ghana (UG), in collaboration with Google Research Africa and the University College of London’s (UCL) ...

"According to the latest study from BCC Research, Antibody Drugs: Technologies and Global Markets is expected to grow from $242.6 billion in 2024 to $412.1 billion ...

The marquee fundraiser of the Women's Guild Cedars-Sinai is set to take place at the Beverly Wilshire, a Four Season Hotel in Beverly Hills on Nov. 21.